The Advances in Gastrointestinal Cancer Resource Centre Introduction
The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting edge data to practising healthcare professionals. Our aim is to provide clinically relevant information in order to enhance the caregivers' ability to provide optimal care for their gastrointestinal (GI) cancer patients. We will offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, will function as a hub of information for healthcare professionals.
Our initial focus for Advances in Gastrointestinal Cancer will centre on gastric cancer, with future expansion to all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
Articles of the Month
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al.Lancet Oncol. 2016 May 3. [Epub ahead of print]
Smyth EC, Cunningham D.Lancet Oncol. 2016 June [Epub ahead of print]
Both articles are selected and commented by Dr Ian Chau:
This month in gastric cancer the result of the KEYNOTE 012 study were published in the Lancet Oncology. This is the first published trial of anti-PD-1 therapy in gastric cancer and provides important proof of concept for the efficacy of these exciting new drugs for gastric cancer patients. In KEYNOTE 012 patients were screened using an immunohistochemistry assay for PD-L1 positivity. Approximately 40% of patients screened were PD-L1 positive and thirty nine patients were treated with the anti-PD-1 antibody pembrolizumab on the trial. Eight patients responded to treatment (22% ORR) and responses were durable with a median duration of response of forty weeks, in fact, half of responding patients had not progressed at the time of study reporting. Pembrolizumab was well tolerated, no patient was withdrawn from treatment due to immune mediated toxicity.
Large randomised trials are ongoing to assess the benefit of anti-PD-1 therapies such as pembrolizumab and nivolumab in patients with gastric cancer. A key questions which remains to be answered is whether PD-L1 positivity is a sensitive and specific biomarker to predict response to such therapies. Additionally, it will be important to address the issue of heterogeneity of biomarker expression which is associated with gastric cancer in order to accurately select patients for treatment.
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)
Hideaki Bando, Toshihiko Doi, Kei Muro, Hirofumi Yasui, Tomohiro Nishina, Kensei Yamaguchi, Shunji Takahashi, Shogo Nomura, Hirofumi Kuno, Kohei Shitara, Akihiro Sato, Atsushi Ohtsu
European Journal of Cancer, July 2016, Pages 46 - 53
Low Preoperative Prognostic Nutritional Index Predicts Poor Survival Post-gastrectomy in Elderly Patients with Gastric Cancer
Sakurai K, Tamura T, Toyokawa T, Amano R, Kubo N, Tanaka H, et al.Ann Surg Oncol. 2016 May 20. [Epub ahead of print]
A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer
Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, et al.Gastric Cancer. 2016 May 17. [Epub ahead of print]
Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging
Tatsubayashi T, Tanizawa Y, Miki Y, Tokunaga M, Bando E, Kawamura T, et al.Gastric Cancer. 2016 May 7. [Epub ahead of print]
Interviews from The European Cancer Congress, Vienna, September, 2015
- Professor Lordick introduces news and his personal highlights from the recent European Cancer Congress 2015 which took place in Vienna,...
- Professor Trevor Leong discusses a randomised trial, TOPGEAR (Trial Of Pre-operative therapy for Gastric and Esophagogastric junction AdenocaRcinoma), which compares...